Medicare Program; Application by American Diabetes Association (ADA) for Continued CMS Approval of Its Diabetes Outpatient Self-Management Training Program, 22211-22213 [2021-08751]
Download as PDF
Federal Register / Vol. 86, No. 79 / Tuesday, April 27, 2021 / Notices
Survey Provider Enhanced Reporting
(CASPER) by the CMS Regional Offices
(ROs). The CMS–1880 form is also
completed by current Medicare
participating portable x-ray supplier
during each recertification survey. Form
Numbers: CMS–1880 (OMB control
number: 0938–0027); Frequency:
Occasionally; Affected Public: State,
Local, or Tribal Governments; Number
of Respondents: 104; Total Annual
Responses: 104; Total Annual Hours:
26. (For policy questions regarding this
collection contact Caroline Gallaher at
410–786–8705.)
Dated: April 21, 2021.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2021–08688 Filed 4–26–21; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–3412–PN]
Medicare Program; Application by
American Diabetes Association (ADA)
for Continued CMS Approval of Its
Diabetes Outpatient Self-Management
Training Program
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice with request for
comment.
AGENCY:
This proposed notice
acknowledges the receipt of an
application from the American Diabetes
Association (ADA) for continued
recognition as a national accrediting
organization (AO) for accrediting
entities that wish to furnish diabetes
outpatient self-management training
services to Medicare beneficiaries.
DATES: To be assured consideration,
comments must be received at one of
the addresses provided below, by May
27, 2021.
ADDRESSES: In commenting, refer to file
code CMS–3412–PN. Because of staff
and resource limitations, we cannot
accept comments by facsimile (FAX)
transmission.
Comments, including mass comment
submissions, must be submitted in one
of the following three ways (please
choose only one of the ways listed):
1. Electronically. You may submit
electronic comments on this regulation
to https://www.regulations.gov. Follow
the ‘‘Submit a comment’’ instructions.
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:52 Apr 26, 2021
Jkt 253001
2. By regular mail. You may mail
written comments to the following
address only: Centers for Medicare &
Medicaid Services, Department of
Health and Human Services, Attention:
CMS–3412–PN, P.O. Box 8010,
Baltimore, MD 21244–8010.
Please allow sufficient time for mailed
comments to be received before the
close of the comment period.
3. By express or overnight mail. You
may send written comments to the
following address only: Centers for
Medicare & Medicaid Services,
Department of Health and Human
Services, Attention: CMS–3412–PN,
Mail Stop C4–26–05, 7500 Security
Boulevard, Baltimore, MD 21244–1850.
For information on viewing public
comments, see the beginning of the
SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT:
Shannon Freeland, (410) 786–4348.
Caroline Gallaher, (410) 786–8705.
Lillian Williams, (410) 786–8636.
SUPPLEMENTARY INFORMATION: Inspection
of Public Comments: All comments
received before the close of the
comment period are available for
viewing by the public, including any
personally identifiable or confidential
business information that is included in
a comment. We post all comments
received before the close of the
comment period on the following
website as soon as possible after they
have been received: https://
www.regulations.gov. Follow the search
instructions on that website to view
public comments. CMS will not post on
Regulations.gov public comments that
make threats to individuals or
institutions or suggest that the
individual will take actions to harm the
individual. CMS continues to encourage
individuals not to submit duplicative
comments. We will post acceptable
comments from multiple unique
commenters even if the content is
identical or nearly identical to other
comments.
I. Background
Diabetes outpatient self-management
training services are defined at section
1861(qq)(1) of the Social Security Act
(the Act) as ‘‘educational and training
services furnished (at such times as the
Secretary determines appropriate) to an
individual with diabetes by a certified
provider (as described in paragraph
(2)(A)) in an outpatient setting by an
individual or entity who meets the
quality standards described in
paragraph (2)(B), but only if the
physician who is managing the
individual’s diabetic condition certifies
that such services are needed under a
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
22211
comprehensive plan of care related to
the individual’s diabetic condition to
ensure therapy compliance or to provide
the individual with necessary skills and
knowledge (including skills related to
the self-administration of injectable
drugs) to participate in the management
of the individual’s condition.’’
In addition, section 1861(qq)(2)(A) of
the Act describes a ‘‘certified provider’’
as a physician, or other individual or
entity designated by the Secretary of the
Department of Health and Human
Services (the Secretary), that, in
addition to providing diabetes
outpatient self-management training
services, provides other items or
services for which payment may be
made under this title. Section
1861(qq)(2)(B) of the Act further
specifies that a physician, or such other
individual or entity, must meet the
quality standards established by the
Secretary, except that the physician or
other individual or entity shall be
deemed to have met such standards if
the physician or other individual or
entity meets applicable standards
originally established by the National
Diabetes Advisory Board and
subsequently revised by organizations
who participated in the establishment of
standards by such Board, or is
recognized by an organization that
represents individuals (including
individuals under this title) with
diabetes as meeting standards for
furnishing the services.
Section 1865 of the statute also
permits the Secretary to use accrediting
bodies to determine whether a provider
entity meets Medicare regulatory quality
standards, such as those established for
diabetes outpatient self-management
training service programs. A national
AO must be approved by CMS and meet
the standards and requirements
specified in 42 CFR part 410, subpart H,
to qualify for Medicare deeming
authority.
Our regulations pertaining to the
application procedures for diabetes
outpatient self-management training
AOs seeking CMS approval are set forth
at § 410.142. A national accreditation
organization applying for deeming
authority must provide CMS with
reasonable assurance that it requires the
diabetes outpatient self-management
training suppliers it accredits to meet
the CMS’ quality standards, the National
Standards for Diabetes Outpatient SelfManagement Education and Support
(NSDSMES) standards, or an alternative
set of standards that meet or exceed our
requirements that have been developed
by that AO and have been approved by
CMS. (See § 410.144.)
E:\FR\FM\27APN1.SGM
27APN1
22212
Federal Register / Vol. 86, No. 79 / Tuesday, April 27, 2021 / Notices
Section 410.142(a) states that ‘‘CMS
may approve and recognize a nonprofit
organization with demonstrated
experience in representing the interests
of individuals with diabetes to accredit
entities to furnish training.’’ Therefore,
diabetes outpatient self-management
training AOs must be not-for-profit
organizations. The national
accreditation organization, after being
approved and recognized by CMS, may
accredit an entity to meet one of the sets
of quality standards in § 410.144.
jbell on DSKJLSW7X2PROD with NOTICES
II. Approval of Accreditation
Organizations
Section 1865(a)(2) of the Act and
§ 410.142 require that our findings from
review of a national AO’s application
consider, among other factors, the
applying AO’s requirements for
accreditation; survey procedures;
resources for conducting required
surveys; capacity to furnish information
for use in enforcement activities;
monitoring procedures for provider
entities found not in compliance with
the conditions or requirements; and
ability to provide the Secretary with the
necessary data for validation.
Section 1865(a)(3) of the Act and
§ 410.142(d) require that we publish,
within 60 days after receipt of an
organization’s complete application, a
notice identifying the national
accrediting body making the request,
describing the nature of the request, and
providing at least a 30-day public
comment period. Section 1865(a)(3)(A)
of the Act further states, we have 210
days from the receipt of a complete
application to publish notice of
approval or denial of the application.
The purpose of this proposed notice
is to inform the public of the American
Diabetes Association’s (ADA’s)
submission of an application requesting
renewal of the CMS approval for its
diabetes outpatient self-management
training accreditation program. This
notice also solicits public comment on
whether ADA’s requirements meet or
exceed the NSDSMES, which are the
accreditation standards used for
certification of the diabetes outpatient
self-management training programs
accredited by the ADA, pursuant to
§ 410.144(b).
III. Evaluation of Deeming Authority
Request
The ADA submitted all the necessary
materials to enable us to make a
determination concerning its request for
renewed CMS approval of its diabetes
outpatient self-management training
accreditation program. This application
was determined to be complete on
March 1, 2021. Under section 1865(a)(2)
VerDate Sep<11>2014
18:52 Apr 26, 2021
Jkt 253001
of the Act and our regulations at
§ 410.142, our review and evaluation of
the ADA’s application will be
conducted in accordance with, but not
necessarily limited to:
• The requirements and quality
standards the ADA uses to accredit
entities to furnish diabetes selfoutpatient management training.
• The accreditation process used by
ADA to determine the following:
++ Frequency of accreditation.
++ Copies of accreditation forms,
guidelines, and instructions to
evaluators.
++ The accreditation review process
and the accreditation status decision
making process.
++ The procedures used to notify a
deemed diabetes outpatient selfmanagement training entity of
deficiencies in its diabetes outpatient
self-management training program and
the procedures used to monitor the
correction of those deficiencies.
++ The procedures used to enforce
compliance with the accreditation
requirements and standards.
++ Detailed information about the
individuals who perform evaluations for
the AO.
++ A description of the AO’s data
management and analysis system for its
accreditation activities and decisions,
including reports, tables, and other
displays generated by that system.
++ A description of the AO’s
procedures for responding to and
investigating complaints against an
approved entity, including policies and
procedures regarding coordination of
these activities with appropriate
licensing bodies, ombudsmen programs,
and CMS.
++ A description of the AO’s policies
and procedures for withholding or
removing a certificate of accreditation
for failure to meet the AO’s standards or
requirements, and other actions the AO
takes in response to noncompliance
with its standards and requirements.
++ A description of all types (for
example, full or partial) and categories
(for example, provisional, conditional,
or temporary) of accreditation offered by
the AO, the duration of each type and
category of accreditation, and a
statement identifying the types and
categories that will serve as a basis for
accreditation if CMS approves the
organization’s, application.
++ A list of all of the approved
entities currently accredited to furnish
diabetes outpatient self-management
training and the type, category, and
expiration date of the accreditation held
by each of them.
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
++ The name and address of each
person with an ownership or control
interest in the AO.
++ Documentation that demonstrates
ADA’s ability to furnish CMS with
electronic data in CMS-compatible
format.
++ A resource analysis that
demonstrates that ADA’s staffing,
funding, and other resources are
adequate to perform the required
accreditation activities.
++ A statement acknowledging that,
as a condition for approval and
recognition by CMS of its accreditation
program, ADA agrees to comply with
the requirements set forth in §§ 410.142
through 410.146.
++ Additional information CMS
requests to enable it to respond to the
AO’s request for CMS approval and
recognition of its diabetes outpatient
self-management training accreditation
program.
Upon completion of our evaluation,
including evaluation of comments
received as a result of this notice, we
will publish a final notice in the Federal
Register announcing the result of our
evaluation.
IV. Collection of Information
Requirements
This document does not impose
information collection requirements,
that is, reporting, recordkeeping or
third-party disclosure requirements.
Consequently, there is no need for
review by the Office of Management and
Budget under the authority of the
Paperwork Reduction Act of 1995 (44
U.S.C. 3501 et seq.).
V. Response to Comments
Because of the large number of public
comments we normally receive on
Federal Register documents, we are not
able to acknowledge or respond to them
individually. We will consider all
comments we receive by the date and
time specified in the DATES section of
this preamble, and, when we proceed
with a subsequent document, we will
respond to the comments in the
preamble to that document.
The Acting Administrator of the
Centers for Medicare & Medicaid
Services (CMS), Elizabeth Richter,
having reviewed and approved this
document, authorizes Lynette Wilson,
who is the Federal Register Liaison, to
electronically sign this document for
purposes of publication in the Federal
Register.
E:\FR\FM\27APN1.SGM
27APN1
Federal Register / Vol. 86, No. 79 / Tuesday, April 27, 2021 / Notices
Dated: April 22, 2021.
Lynette Wilson,
Federal Register Liaison, Centers for Medicare
& Medicaid Services.
[FR Doc. 2021–08751 Filed 4–26–21; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–D–0320]
Nonclinical Testing of Individualized
Antisense Oligonucleotide Drug
Products for Severely Debilitating or
Life-Threatening Diseases; Draft
Guidance for Sponsor-Investigators;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a draft
guidance for industry entitled
‘‘Nonclinical Testing of Individualized
Antisense Oligonucleotide Drug
Products for Severely Debilitating or
Life-Threatening Diseases.’’ FDA is
publishing this draft guidance to help
sponsor-investigators (hereafter referred
to as sponsors) with developing the
nonclinical information that FDA
recommends to support an
investigational new drug application
(IND) for certain individualized
antisense oligonucleotide (ASO) drug
products. ASO drug products that are
the focus of this draft guidance are those
being developed to treat rapidly
progressing, severely debilitating or lifethreatening (SDLT) disease attributable
to a unique genetic variant or variants
that may be amenable to RNA-directed
treatment.
DATES: Submit either electronic or
written comments on the draft guidance
by June 28, 2021 to ensure that the
Agency considers your comment on this
draft guidance before it begins work on
the final version of the guidance.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
VerDate Sep<11>2014
18:52 Apr 26, 2021
Jkt 253001
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2021–D–0320 for ‘‘Nonclinical Testing
of Individualized Antisense
Oligonucleotide Drug Products for
Severely Debilitating or LifeThreatening Diseases.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
PO 00000
Frm 00084
Fmt 4703
Sfmt 4703
22213
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single
copies of the draft guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10001 New
Hampshire Ave., Hillandale Building,
4th Floor, Silver Spring, MD 20993–
0002. Send one self-addressed adhesive
label to assist that office in processing
your requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the draft guidance document.
FOR FURTHER INFORMATION CONTACT:
Ronald Wange, Center for Drug
Evaluation and Research (HFD–510),
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 22, Rm.
3342, Silver Spring, MD 20903, 301–
796–1304.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a draft guidance for industry entitled
‘‘Nonclinical Testing of Individualized
Antisense Oligonucleotide Drug
Products for Severely Debilitating or
Life-Threatening Diseases.’’ FDA is
publishing this draft guidance, that,
when finalized, will help sponsors with
developing the nonclinical information
that FDA recommends to support an
IND for certain individualized ASO
drug products. ASO drug products that
are the focus of this draft guidance are
those being developed to treat a rapidly
progressing, SDLT disease attributable
E:\FR\FM\27APN1.SGM
27APN1
Agencies
[Federal Register Volume 86, Number 79 (Tuesday, April 27, 2021)]
[Notices]
[Pages 22211-22213]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-08751]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-3412-PN]
Medicare Program; Application by American Diabetes Association
(ADA) for Continued CMS Approval of Its Diabetes Outpatient Self-
Management Training Program
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Notice with request for comment.
-----------------------------------------------------------------------
SUMMARY: This proposed notice acknowledges the receipt of an
application from the American Diabetes Association (ADA) for continued
recognition as a national accrediting organization (AO) for accrediting
entities that wish to furnish diabetes outpatient self-management
training services to Medicare beneficiaries.
DATES: To be assured consideration, comments must be received at one of
the addresses provided below, by May 27, 2021.
ADDRESSES: In commenting, refer to file code CMS-3412-PN. Because of
staff and resource limitations, we cannot accept comments by facsimile
(FAX) transmission.
Comments, including mass comment submissions, must be submitted in
one of the following three ways (please choose only one of the ways
listed):
1. Electronically. You may submit electronic comments on this
regulation to https://www.regulations.gov. Follow the ``Submit a
comment'' instructions.
2. By regular mail. You may mail written comments to the following
address only: Centers for Medicare & Medicaid Services, Department of
Health and Human Services, Attention: CMS-3412-PN, P.O. Box 8010,
Baltimore, MD 21244-8010.
Please allow sufficient time for mailed comments to be received
before the close of the comment period.
3. By express or overnight mail. You may send written comments to
the following address only: Centers for Medicare & Medicaid Services,
Department of Health and Human Services, Attention: CMS-3412-PN, Mail
Stop C4-26-05, 7500 Security Boulevard, Baltimore, MD 21244-1850.
For information on viewing public comments, see the beginning of
the SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT:
Shannon Freeland, (410) 786-4348.
Caroline Gallaher, (410) 786-8705.
Lillian Williams, (410) 786-8636.
SUPPLEMENTARY INFORMATION: Inspection of Public Comments: All comments
received before the close of the comment period are available for
viewing by the public, including any personally identifiable or
confidential business information that is included in a comment. We
post all comments received before the close of the comment period on
the following website as soon as possible after they have been
received: https://www.regulations.gov. Follow the search instructions on
that website to view public comments. CMS will not post on
Regulations.gov public comments that make threats to individuals or
institutions or suggest that the individual will take actions to harm
the individual. CMS continues to encourage individuals not to submit
duplicative comments. We will post acceptable comments from multiple
unique commenters even if the content is identical or nearly identical
to other comments.
I. Background
Diabetes outpatient self-management training services are defined
at section 1861(qq)(1) of the Social Security Act (the Act) as
``educational and training services furnished (at such times as the
Secretary determines appropriate) to an individual with diabetes by a
certified provider (as described in paragraph (2)(A)) in an outpatient
setting by an individual or entity who meets the quality standards
described in paragraph (2)(B), but only if the physician who is
managing the individual's diabetic condition certifies that such
services are needed under a comprehensive plan of care related to the
individual's diabetic condition to ensure therapy compliance or to
provide the individual with necessary skills and knowledge (including
skills related to the self-administration of injectable drugs) to
participate in the management of the individual's condition.''
In addition, section 1861(qq)(2)(A) of the Act describes a
``certified provider'' as a physician, or other individual or entity
designated by the Secretary of the Department of Health and Human
Services (the Secretary), that, in addition to providing diabetes
outpatient self-management training services, provides other items or
services for which payment may be made under this title. Section
1861(qq)(2)(B) of the Act further specifies that a physician, or such
other individual or entity, must meet the quality standards established
by the Secretary, except that the physician or other individual or
entity shall be deemed to have met such standards if the physician or
other individual or entity meets applicable standards originally
established by the National Diabetes Advisory Board and subsequently
revised by organizations who participated in the establishment of
standards by such Board, or is recognized by an organization that
represents individuals (including individuals under this title) with
diabetes as meeting standards for furnishing the services.
Section 1865 of the statute also permits the Secretary to use
accrediting bodies to determine whether a provider entity meets
Medicare regulatory quality standards, such as those established for
diabetes outpatient self-management training service programs. A
national AO must be approved by CMS and meet the standards and
requirements specified in 42 CFR part 410, subpart H, to qualify for
Medicare deeming authority.
Our regulations pertaining to the application procedures for
diabetes outpatient self-management training AOs seeking CMS approval
are set forth at Sec. 410.142. A national accreditation organization
applying for deeming authority must provide CMS with reasonable
assurance that it requires the diabetes outpatient self-management
training suppliers it accredits to meet the CMS' quality standards, the
National Standards for Diabetes Outpatient Self-Management Education
and Support (NSDSMES) standards, or an alternative set of standards
that meet or exceed our requirements that have been developed by that
AO and have been approved by CMS. (See Sec. 410.144.)
[[Page 22212]]
Section 410.142(a) states that ``CMS may approve and recognize a
nonprofit organization with demonstrated experience in representing the
interests of individuals with diabetes to accredit entities to furnish
training.'' Therefore, diabetes outpatient self-management training AOs
must be not-for-profit organizations. The national accreditation
organization, after being approved and recognized by CMS, may accredit
an entity to meet one of the sets of quality standards in Sec.
410.144.
II. Approval of Accreditation Organizations
Section 1865(a)(2) of the Act and Sec. 410.142 require that our
findings from review of a national AO's application consider, among
other factors, the applying AO's requirements for accreditation; survey
procedures; resources for conducting required surveys; capacity to
furnish information for use in enforcement activities; monitoring
procedures for provider entities found not in compliance with the
conditions or requirements; and ability to provide the Secretary with
the necessary data for validation.
Section 1865(a)(3) of the Act and Sec. 410.142(d) require that we
publish, within 60 days after receipt of an organization's complete
application, a notice identifying the national accrediting body making
the request, describing the nature of the request, and providing at
least a 30-day public comment period. Section 1865(a)(3)(A) of the Act
further states, we have 210 days from the receipt of a complete
application to publish notice of approval or denial of the application.
The purpose of this proposed notice is to inform the public of the
American Diabetes Association's (ADA's) submission of an application
requesting renewal of the CMS approval for its diabetes outpatient
self-management training accreditation program. This notice also
solicits public comment on whether ADA's requirements meet or exceed
the NSDSMES, which are the accreditation standards used for
certification of the diabetes outpatient self-management training
programs accredited by the ADA, pursuant to Sec. 410.144(b).
III. Evaluation of Deeming Authority Request
The ADA submitted all the necessary materials to enable us to make
a determination concerning its request for renewed CMS approval of its
diabetes outpatient self-management training accreditation program.
This application was determined to be complete on March 1, 2021. Under
section 1865(a)(2) of the Act and our regulations at Sec. 410.142, our
review and evaluation of the ADA's application will be conducted in
accordance with, but not necessarily limited to:
The requirements and quality standards the ADA uses to
accredit entities to furnish diabetes self-outpatient management
training.
The accreditation process used by ADA to determine the
following:
++ Frequency of accreditation.
++ Copies of accreditation forms, guidelines, and instructions to
evaluators.
++ The accreditation review process and the accreditation status
decision making process.
++ The procedures used to notify a deemed diabetes outpatient self-
management training entity of deficiencies in its diabetes outpatient
self-management training program and the procedures used to monitor the
correction of those deficiencies.
++ The procedures used to enforce compliance with the accreditation
requirements and standards.
++ Detailed information about the individuals who perform
evaluations for the AO.
++ A description of the AO's data management and analysis system
for its accreditation activities and decisions, including reports,
tables, and other displays generated by that system.
++ A description of the AO's procedures for responding to and
investigating complaints against an approved entity, including policies
and procedures regarding coordination of these activities with
appropriate licensing bodies, ombudsmen programs, and CMS.
++ A description of the AO's policies and procedures for
withholding or removing a certificate of accreditation for failure to
meet the AO's standards or requirements, and other actions the AO takes
in response to noncompliance with its standards and requirements.
++ A description of all types (for example, full or partial) and
categories (for example, provisional, conditional, or temporary) of
accreditation offered by the AO, the duration of each type and category
of accreditation, and a statement identifying the types and categories
that will serve as a basis for accreditation if CMS approves the
organization's, application.
++ A list of all of the approved entities currently accredited to
furnish diabetes outpatient self-management training and the type,
category, and expiration date of the accreditation held by each of
them.
++ The name and address of each person with an ownership or control
interest in the AO.
++ Documentation that demonstrates ADA's ability to furnish CMS
with electronic data in CMS-compatible format.
++ A resource analysis that demonstrates that ADA's staffing,
funding, and other resources are adequate to perform the required
accreditation activities.
++ A statement acknowledging that, as a condition for approval and
recognition by CMS of its accreditation program, ADA agrees to comply
with the requirements set forth in Sec. Sec. 410.142 through 410.146.
++ Additional information CMS requests to enable it to respond to
the AO's request for CMS approval and recognition of its diabetes
outpatient self-management training accreditation program.
Upon completion of our evaluation, including evaluation of comments
received as a result of this notice, we will publish a final notice in
the Federal Register announcing the result of our evaluation.
IV. Collection of Information Requirements
This document does not impose information collection requirements,
that is, reporting, recordkeeping or third-party disclosure
requirements. Consequently, there is no need for review by the Office
of Management and Budget under the authority of the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501 et seq.).
V. Response to Comments
Because of the large number of public comments we normally receive
on Federal Register documents, we are not able to acknowledge or
respond to them individually. We will consider all comments we receive
by the date and time specified in the DATES section of this preamble,
and, when we proceed with a subsequent document, we will respond to the
comments in the preamble to that document.
The Acting Administrator of the Centers for Medicare & Medicaid
Services (CMS), Elizabeth Richter, having reviewed and approved this
document, authorizes Lynette Wilson, who is the Federal Register
Liaison, to electronically sign this document for purposes of
publication in the Federal Register.
[[Page 22213]]
Dated: April 22, 2021.
Lynette Wilson,
Federal Register Liaison, Centers for Medicare & Medicaid Services.
[FR Doc. 2021-08751 Filed 4-26-21; 8:45 am]
BILLING CODE 4120-01-P